ReviewTherapeutics and clinical risk management2020
Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges.
Review in Therapeutics and clinical risk management, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 49 citations in OpenAlex.
- Evaluation of validity, reliability and ability to detect change for the Hand Eczema Severity Index (HECSI) and evaluation of HECSI-75 and HECSI-90 as within-patient responder definitions.Contact dermatitis · 2025Trial
- Patient Preferences for Treatment Attributes in Moderate to Severe Chronic Hand Eczema: A Discrete Choice Experiment.Dermatology and therapy · 2026Article
- Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 Trial.Dermatology and therapy · 2026Article
- Real-Life Workup of Chronic Hand Eczema Using a Dedicated Case Report Form: A SIDAPA Multicentre Study.Contact dermatitis · 2026Article
- Treatment Patterns and Economic Burden in Moderate to Severe Chronic Hand Eczema in the USA: A Real-World Retrospective Claims Analysis.Dermatology and therapy · 2026Article
- A Retrospective Real-World Comparison of Topical Delgocitinib and Localized Cream Psoralen-Ultraviolet A in Chronic Hand Eczema.Dermatology and therapy · 2026Article
- Molecular Diagnostics in Hand Dermatoses: Clinical Findings and Health-Related Quality of Life in a 3-Year Follow-Up Cohort Study.Dermatology and therapy · 2026Article
- Expert Recommendations for the Diagnosis and Management of Chronic Hand Eczema in the United States.American journal of clinical dermatology · 2026Review
- Delgocitinib Cream Reduces Itch and Pain in Moderate to Severe Chronic Hand Eczema: Phase 3 DELTA 1 and 2 Pooled Analyses.Dermatology and therapy · 2026Article
- Exploring Two New, Validated Disease-Specific Outcome Measures to Assess Severity of Chronic Hand Eczema: Investigator Global Assessment of Chronic Hand Eczema (IGA-CHE) and Hand Eczema Symptom Diary (HESD)-A Podcast.Dermatology and therapy · 2026Article
- Review
- Empathy for the Patient with Chronic Hand Eczema.Dermatology and therapy · 2026Article
- Efficacy and Safety of Runzaozhiyang Lotion for Chronic Hand Eczema: Protocol for a Randomized Controlled Trial.JMIR research protocols · 2025Article
- A Practical Approach to Chronic Hand Eczema.Dermatology and therapy · 2025Article
- Health-Related Quality of Life in Chronic Hand Eczema in a Phase 2b Trial of Delgocitinib Cream.Dermatology and therapy · 2025Article
- Chronic Hand Eczema, Real World, and Patient Centricity: A Narrative Review.Acta dermato-venereologica · 2025Review
- Chronic Hand Eczema (CHE): A Narrative Review.Dermatology and therapy · 2025Review
- Italian Expert Opinion on Chronic Hand Eczema: from Guidelines to Clinical Practice.Dermatology and therapy · 2025Article
- Risk factors that limit use of oral JAK inhibitors in chronic hand eczema: Findings from the Danish Skin Cohort.JAAD international · 2024Article
- New Perspectives in the Management of Chronic Hand Eczema: Lessons from Pathogenesis.International journal of molecular sciences · 2023Review
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic hand eczema (CHE) is a common and burdensome inflammatory skin condition seen in up to 10% of the population, more often in high-risk occupational workers. Topical therapeutics comprise the standard of care, but up to 65% of cases do not resolve after treatment, and moderate-to-severe cases are often resistant to topical therapeutics and require systemic options instead. To date, there are no systemic therapeutics approved to treat CHE in the United States, but several drugs are under investigation as potential treatments for CHE. The primary focus of this review is on the novel therapeutics, topical and systemic, that are under investigation in recently completed or currently ongoing trials. This review also briefly outlines the existing treatments utilized for CHE, often with limited success or extensive adverse effects. CHE represents a major challenge for physicians and patients alike, and efforts to improve the minimally invasive diagnostic tools and treatment paradigms are ongoing. In the near future, CHE patients may benefit from new topical and systemic therapeutics that specifically target abnormally expressed immune markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.